权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Identifying the role of the gut microbiome in the etiology of benign breast disease

确定肠道微生物组在良性乳腺疾病病因学中的作用

基本信息

批准号：
10642675
负责人：
Tengteng Wang
金额：
$ 16.9万
依托单位：
BRIGHAM AND WOMEN'S HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-06-10 至 2023-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10642675
关键词：
16S ribosomal RNA sequencing Age Age at Menarche Applications Grants Attention Award Bacteria Bacteroides Benign Bioinformatics Biopsy Breast Breast Cancer Epidemiology Breast Cancer Prevention Breast Diseases Breast biopsy Cancer Etiology Catalogs Cessation of life Classification Collaborations Collection Data Data Analyses Data Set Development Diagnosis Environment Epidemiology Estrogens Etiology Event Exogenous Hormone Therapy Feces First Births Fostering Future Goals High Risk Woman Homeostasis Hormonal Hormonal Risk Factor Hormones Hospitals Human Microbiome Intervention Knowledge Lesion Link Liquid Chromatography Measurement Mediating Mentors Metabolism Metagenomics Methods Morbidity - disease rate Multiomic Data Nested Case-Control Study Nulliparity Nurses Nurses&apos Health Study Oral Contraceptives Participant Pathogenesis Pathologic Pathologist Pathology Pathway interactions Play Productivity Proliferative Type Breast Fibrocystic Change Prospective Studies Reporting Reproductive History Research Research Personnel Retrospective Studies Risk Risk Factors Risk Reduction Role Sample Size Shotguns Strategic vision Taxonomy Testing Tissue Sample Training United States Variant Woman biomedical scientist breast pathology career cohort disease diagnosis disorder risk disorder subtype experience fecal microbiome gut microbes gut microbiome gut microbiota high risk innovation malignant breast neoplasm menopausal hormone therapy metabolome metabolomics metagenomic sequencing microbial microbial community microbial signature microbiome microbiome composition microbiome research microbiota microbiota metabolites mortality multidisciplinary multiple omics novel premalignant programs prospective reproductive risk prediction sample collection small molecule stool sample tandem mass spectrometry

项目摘要

PROJECT SUMMARY/ABSTRACT The overall goal of this project is to identify the role of the gut microbiome in the etiology of benign breast disease (BBD), and thereby shed light on its pathogenesis in relation to breast cancer. Approximately one out of every five women in the United States has been diagnosed with BBD, a well-established risk indicator for breast cancer. BBD share the hormonal-related risk factors with breast cancer. However, the underlying mechanisms linking hormone factors and breast disease are not clear. Emerging evidence suggests that the gut microbiome may be significantly involved in breast disease through the influence on systemic estrogen homeostasis. This evidence supports the hypothesis that the gut microbiome is a key player in breast disease, and it may mediate the associations between hormonal risk factors and BBD. However, no study has systematically studied the role of the gut microbiome and its metabolome on BBD. Dr. Wang proposes to be the first to test this important hypothesis. She will leverage the sub-studies embedded in the well-characterized Nurses’ Health Study II, to test the three specific aims. In Aim 1 (K99), she will identify potential differences in gut microbial composition and functional variation by various hormonal factors among ~1800 participants. In Aim 2 (R00), she will characterize the associations between gut microbiome composition and the high-risk, proliferative subtype of BBD in a nested case-control study (N=300) with breast biopsy sample collection. In Aim 3 (R00), she will incorporate the functional readout of gut microbiome, the fecal metabolomics, to estimate the associations between microbial metabolomic signatures and BBD in the same nested case-control study. Innovative shotgun metagenomic sequencing and semi-targeted metabolomics will be used to discover microbial strains and their metabolites. By integrating metagenomics and metabolomics, she will comprehensively investigate taxonomic composition and functional potential of gut microbial communities that are directly involved in BBD, as well as the potential mediating role of the gut microbiome underlying the hormonal factors-BBD associations. Results from the proposed study may pave the way for novel personalized BBD and breast cancer prevention for high- risk women defined by their hormonal profiles, with the potential modulation of gut microbiome. Dr. Wang’s research aims are supported by a well-rounded training plan tailored to her two training goals: 1) Obtain training and apply advanced bioinformatic analytics to large microbiome metagenomic and metabolomics datasets; and 2) Develop advanced knowledge on hormonal determinants on BBD epidemiology, etiology, pathology, and pathogenesis as it relates to breast cancer. The training environment at Brigham and Women’s Hospital fosters productivity and collaboration with world class biomedical scientists, and she have assembled a multidisciplinary mentoring team that includes leading experts in BBD, human microbiome, bioinformatics, hormonal factors, breast pathology, and breast cancer epidemiology. This K99/R00 award will help her gain the knowledge and experience necessary to effectively pursue her career as an independent breast cancer investigator.

项目总结/文摘